Abdullahi Mubarak, MD
Addiction Medicine · Centerville, OHNPI 1861521940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 374 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 24.3% of the total. Among addiction medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 374 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Collegium Pharmaceutical, Inc.$964
- Indivior Inc.$480
- Otsuka America Pharmaceutical, Inc.$377
- Alkermes, Inc.$358
- Axsome Therapeutics, Inc.$243
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,145100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $1,501 |
| Collegium Pharmaceutical, Inc. | 68 | $964 |
| Indivior Inc. | 22 | $480 |
| Otsuka America Pharmaceutical, Inc. | 16 | $377 |
| Alkermes, Inc. | 15 | $358 |
| Axsome Therapeutics, Inc. | 13 | $243 |
| Orexo US, Inc. | 15 | $229 |
| Biodelivery Sciences International, Inc. | 15 | $221 |
| Pfizer | 6 | $214 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $174 |
| Lundbeck LLC | 7 | $163 |
| Novartis | 10 | $155 |
| Lilly USA, LLC | 11 | $153 |
| Nestle Healthcare Nutrition Inc. | 9 | $146 |
| Almatica Pharma LLC | 6 | $144 |
| Braeburn Inc. | 6 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $105 |
| AstraZeneca | 4 | $95 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Novo Nordisk | 3 | $37 |
| MDD US Operations, LLC | 2 | $26 |
| Virtus Pharmaceuticals LLC | 1 | $21 |
| Kaleo, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Protega Pharmaceutials Inc | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$6,171 in reported general payments places this provider in the 90th percentile of 98 addiction medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 97 | $184,862 |
| Xtampza ErOxycodone Myristate | 88 | $161,496 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 339 | $76,712 |
| OzempicSemaglutide | 38 | $51,145 |
| Hysingla ErHydrocodone Bitartrate | 40 | $46,214 |
| CreonLipase/Protease/Amylase | 27 | $41,371 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 26 | $28,464 |
| QuliptaAtogepant | 17 | $24,092 |
| Oxymorphone Hcl ErOxymorphone Hcl | 14 | $21,401 |
| UbrelvyUbrogepant | 13 | $20,205 |
| Hydromorphone ErHydromorphone Hcl | 12 | $20,169 |
| XareltoRivaroxaban | 28 | $19,529 |
| EliquisApixaban | 22 | $17,916 |
| LyricaPregabalin | 20 | $17,823 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $16,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta | $964 | $172,035100 claims |
| AbbVieCreon, Qulipta, Ubrelvy, Linzess | $1,501 | $92,20169 claims |
| Novo NordiskOzempic | $37 | $51,14538 claims |
| PfizerEliquis, Lyrica | $214 | $35,73942 claims |
| Orexo US, Inc.Zubsolv | $229 | $28,46426 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $15 | $20,11137 claims |
| Indivior Inc.Suboxone | $480 | $16,50727 claims |
| AstraZenecaBreztri Aerosphere | $95 | $16,50727 claims |
| NovartisEntresto | $155 | $16,21316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 addiction medicine providers in Ohio.
Other addiction medicine in Centerville
- Parag PatelCincinnati$171K
- Stephanie TraylorColumbus$86K
- Wayne KawalekOakwood Village$82K
- Nicole LaborAkron$17K
- Orman HallColumbus$10K
- Puja SrivastavaWilmington$9K
- David KesegChillicothe$8K
- Timothy SuttonMansfield$6K
- Robert MasoneColumbus$6K
- Angelice Alexander-MartinColumbus$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.